Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Amcinonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 7/20 | 0.77 |
| ▸ | LMNA | P02545 | 7/20 | 0.77 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.77 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.77 |
| ▸ | PGR | P06401 | 6/20 | 0.77 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.77 |
| ▸ | MAPT | P10636 | 2/20 | 0.77 |
| ▸ | CNR1 | P21554 | 1/20 | 0.77 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.77 |
| ▸ | USP2 | O75604 | 1/20 | 0.77 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Amcinonide SCHEMBL22684943 | 0.91 | NR3C1 (0.64) | LMNANR3C1HIF1ACYP3A4PGR | |
| Fluocinonide SCHEMBL616754 | 0.89 | NR3C1 (0.74) | LMNANR3C1HIF1ACYP3A4PGR | |
| Amcinonide SCHEMBL13026154 | 0.88 | HIF1A (1.00) | LMNANR3C1HIF1ACYP3A4PGR | |
| Amcinonide SCHEMBL1649481 | 0.88 | HIF1A (1.00) | LMNANR3C1HIF1ACYP3A4PGR | |
| Amcinonide SCHEMBL12396698 | 0.88 | HIF1A (1.00) | LMNANR3C1HIF1ACYP3A4PGR | |
| Amcinonide SCHEMBL5488922 | 0.88 | HIF1A (1.00) | LMNANR3C1HIF1ACYP3A4PGR | |
| Amcinonide SCHEMBL4720 | 0.88 | HIF1A (1.00) | LMNANR3C1HIF1ACYP3A4PGR | |
| Amcinonide SCHEMBL21051752 | 0.88 | HIF1A (1.00) | LMNANR3C1HIF1ACYP3A4PGR | |
| Desonide SCHEMBL2115498 | 0.87 | CYP3A4 (0.75) | LMNANR3C1HIF1ACYP3A4PGR | |
| Desonide SCHEMBL11778722 | 0.86 | CYP3A4 (0.73) | LMNANR3C1HIF1ACYP3A4PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1207042-A | A Pharmaceutical composition for the treatment of autommune diseases | ANGELINT RICERCHE S P A SOCIET (IT) | 1999-02-03 | — | — | CN | claimed |
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC (US) | 2020-12-24 | — | — | US | disclosed |
| US-20200147084-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. | 2020-05-14 | — | — | US | disclosed |
| US-20180071293-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. | 2018-03-15 | — | — | US | disclosed |
| US-9717731-B2 | TEC family kinase inhibitor adjuvant therapy | PHARMACYCLICS LLC (US) | 2017-08-01 | — | — | US | disclosed |
| WO-2017053823-A1 | TREATMENT USING HDAC INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS LLC (US) | 2017-03-30 | — | — | WO | disclosed |
| EP-3060251-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | Pharmacyclics LLC (US) | 2016-08-31 | — | — | EP | disclosed |
| CN-105848680-A | Treatment using bruton's tyrosine kinase inhibitors and immunotherapy | 药品循环有限责任公司 | 2016-08-10 | — | — | CN | disclosed |
| EP-2914263-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | Pharmacyclics, Inc. (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015061752-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | PHARMACYCLICS, INC. (US) | 2015-04-30 | — | — | WO | disclosed |
| US-20140371241-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140134265-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. (US) | 2014-05-15 | — | — | US | disclosed |
| WO-2014071231-A1 | TEC FAMILY KINASE INHIBITOR ADJUVANT THERAPY | PHARMACYCLICS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20110218512-A1 | ENHANCED ANTIVIRAL THERAPY METHODS AND DEVICES | AETHLON MEDICAL, INC. (US) | 2011-09-08 | — | — | US | disclosed |
| EP-2318031-A2 | ENHANCED ANTIVIRAL THERAPY METHODS AND DEVICES | Aethlon Medical Inc (US) | 2011-05-11 | — | — | EP | disclosed |
| WO-2009149179-A2 | ENHANCED ANTIVIRAL THERAPY METHODS AND DEVICES | AETHLON MEDICAL INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-0858337-B1 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTOIMMUNE DISEASES | ACRAF (IT) | 2006-05-24 | — | — | EP | disclosed |
| CN-1229113-C | Pharmaceutical composition for treating autoimmune diseases | ANGELINT RICERCHE S P A SOCIET (IT) | 2005-11-30 | — | — | CN | disclosed |
| US-6020356-A | SYNERGISTIC MIXTURE OF BINDARIT, IMMUNOSUPPRESSANT AND EXCIPIENT | ANGELINI RICERCHE S.P.A. SOCIETA' CONSORTILE (IT) | 2000-02-01 | — | — | US | disclosed |
| CN-1207042-A | A Pharmaceutical composition for the treatment of autommune diseases | ANGELINT RICERCHE S P A SOCIET (IT) | 1999-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397895-A1 | TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY | BTK, LCK, LYN | NR3C1 1384/4885LMNA 3880/4885HIF1A 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.